PRR11 Promotes Bladder Cancer Growth and Metastasis by Facilitating G1 /S Progression and Epithelial‐Mesenchymal Transition
Cancer Medicine · 2025
DOI: 10.1002/cam4.70749 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Lu Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Qingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Epithelial-Mesenchymal Transition. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: People's Livelihood Science and Technology Project of Qingdao, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Background
Although Proline‐rich Protein 11 (PRR11) abnormalities are closely associated with carcinogenesis, the precise mechanism of bladder cancer remains unclear. Here, we sought to elucidate the molecular mechanisms of PRR11 in bladder cancer.
Methods
We performed differential expression analysis of PRR11 from the TCGA and GEO databases, followed by validation with clinical samples. Survival analysis was employed to assess the correlation between PRR11 and patient prognosis. The effects of PRR11 on bladder cancer cells were examined through both in vitro and in vivo experiments. Additionally, Gene Set Enrichment Analysis (GSEA) was used to predict the downstream pathways associated with PRR11, which were further validated through subsequent experiments.
Results
PRR11 is upregulated in bladder cancer and could lead to poor prognosis. In vitro, PRR11 promoted tumor cell proliferation; in vivo, it promoted subcutaneous tumor growth. PRR11 knockdown inhibited its oncogenic function. On the molecular level, PRR11 promotes tumor metastasis by inducing Epithelial‐mesenchymal Transition (EMT). GSEA suggests that PRR11 is strongly linked to the cell cycle, and silencing of PRR11 can achieve anti‐tumor effects by inhibiting CCNE and blocking the G1/S phase transition.
Conclusions
Our study demonstrates that silencing PRR11 can arrest the malignant progression of bladder cancer by inhibiting EMT and blocking the G1/S transition. Targeting PRR11 may provide new insights for targeting cell cycle therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Qingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
- Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
- Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.
- Life Sciences, Faculty of Arts & Science, University of Toronto-St. George Campus, Toronto, Canada.
- Faculty of Information Science and Engineering, Ocean University of China, Qingdao, China.
ORCID-Profile: Hai Zhu
Förderung
- People's Livelihood Science and Technology Project of Qingdao
- Natural Science Foundation of Shandong Province
Zitieren
APA
Wang, L., Kou, Z., Zhu, J., Zhu, X., Gao, L., & Zhu, H. (2025). PRR11 Promotes Bladder Cancer Growth and Metastasis by Facilitating G1 /S Progression and Epithelial‐Mesenchymal Transition. Cancer Medicine. https://doi.org/10.1002/cam4.70749
Vancouver
Wang L, Kou Z, Zhu J, Zhu X, Gao L, Zhu H. PRR11 Promotes Bladder Cancer Growth and Metastasis by Facilitating G1 /S Progression and Epithelial‐Mesenchymal Transition. Cancer Medicine. 2025. doi:10.1002/cam4.70749
BibTeX
@article{Wang2025,
author = {Wang, Lu and Kou, Zengshun and Zhu, Jiaxi and Zhu, Xiu and Gao, Lei and Zhu, Hai},
title = {PRR11 Promotes Bladder Cancer Growth and Metastasis by Facilitating G1 /S Progression and Epithelial‐Mesenchymal Transition},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70749}
}
EUVIMED